 BAUDETTE, Minn.--BUSINESS WIRE--ANI Pharmaceuticals, Inc. ANI or the Company Nasdaq: ANIP today announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. ANIs Nebivolol Tablets is the generic version of the reference listed drug RLD Bystolic. The current annual U.S. market for Bystolic 2.5 mg, 5 mg, 10 mg, and 20 mg strengths is approximately 1.05 billion, according to IQVIAIMS Health, a leading healthcare data and analytics provider. The launch of Nebivolol 